| NNMT switches the proangiogenic phenotype of cancer-associated fibroblasts via epigenetically regulating ETS2/VEGFA axis. | NNMT switches the proangiogenic phenotype of cancer-associated fibroblasts via epigenetically regulating ETS2/VEGFA axis.
Wang X, Zhao H, Luo X, Chen Y, Shi C, Wang Y, Bai J, Shao Z, Shang Z. | 08/28/2024 |
| ID2-ETS2 axis regulates the transcriptional acquisition of pro-tumoral microglia phenotype in glioma. | ID2-ETS2 axis regulates the transcriptional acquisition of pro-tumoral microglia phenotype in glioma.
Vázquez-Cabrera G, Škandík M, Roncier N, Real Oualit F, Cruz De Los Santos M, Baleviciute A, Cheray M, Joseph B., Free PMC Article | 08/16/2024 |
| A disease-associated gene desert directs macrophage inflammation through ETS2. | A disease-associated gene desert directs macrophage inflammation through ETS2.
Stankey CT, Bourges C, Haag LM, Turner-Stokes T, Piedade AP, Palmer-Jones C, Papa I, Silva Dos Santos M, Zhang Q, Cameron AJ, Legrini A, Zhang T, Wood CS, New FN, Randzavola LO, Speidel L, Brown AC, Hall A, Saffioti F, Parkes EC, Edwards W, Direskeneli H, Grayson PC, Jiang L, Merkel PA, Saruhan-Direskeneli G, Sawalha AH, Tombetti E, Quaglia A, Thorburn D, Knight JC, Rochford AP, Murray CD, Divakar P, Green M, Nye E, MacRae JI, Jamieson NB, Skoglund P, Cader MZ, Wallace C, Thomas DC, Lee JC., Free PMC Article | 06/26/2024 |
| USP39-Mediated Non-Proteolytic Control of ETS2 Suppresses Nuclear Localization and Activity. | USP39-Mediated Non-Proteolytic Control of ETS2 Suppresses Nuclear Localization and Activity.
Choi Y, Lee Y, Kim JS, Zhang P, Kim J., Free PMC Article | 11/1/2023 |
| ETS2 promotes cardiomyocyte apoptosis and autophagy in heart failure by regulating lncRNA TUG1/miR-129-5p/ATG7 axis. | ETS2 promotes cardiomyocyte apoptosis and autophagy in heart failure by regulating lncRNA TUG1/miR-129-5p/ATG7 axis.
Tan L, Xiong D, Zhang H, Xiao S, Yi R, Wu J. | 05/18/2023 |
| ETS2 alleviates acute-on-chronic liver failure by suppressing excessive inflammation. | ETS2 alleviates acute-on-chronic liver failure by suppressing excessive inflammation.
He L, Cai Q, Liang X, Xin J, Shi D, Ren K, Li Y, Chen J, Sun S, Guo B, Yang H, Li B, Ma S, Luo J, Hu M, Li J, Hu W, Li P, Yao H, Li J, Chen X, Jiang J, Li J. | 05/17/2023 |
| Suppression of USP7 negatively regulates the stability of ETS proto-oncogene 2 protein. | Suppression of USP7 negatively regulates the stability of ETS proto-oncogene 2 protein.
Park HB, Min Y, Hwang S, Baek KH. | 05/17/2023 |
| A novel tissue specific alternative splicing variant mitigates phenotypes in Ets2 frame-shift mutant models. | A novel tissue specific alternative splicing variant mitigates phenotypes in Ets2 frame-shift mutant models.
Kishimoto Y, Nishiura I, Hirata W, Yuri S, Yamamoto N, Ikawa M, Isotani A., Free PMC Article | 11/22/2021 |
| Codon Optimization, Cloning, Expression, Purification, and Secondary Structure Determination of Human ETS2 Transcription Factor. | Codon Optimization, Cloning, Expression, Purification, and Secondary Structure Determination of Human ETS2 Transcription Factor.
Haridhasapavalan KK, Sundaravadivelu PK, Thummer RP. | 06/12/2021 |
| Transcription factor Ets-2 regulates the expression of key lymphotropic factors. | Transcription factor Ets-2 regulates the expression of key lymphotropic factors.
Davoulou P, Aggeletopoulou I, Panagoulias I, Georgakopoulos T, Mouzaki A. | 05/22/2021 |
| DeltaNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. | ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
Cam M, Charan M, Welker AM, Dravid P, Studebaker AW, Leonard JR, Pierson CR, Nakano I, Beattie CE, Hwang EI, Kambhampati M, Nazarian J, Finlay JL, Cam H., Free PMC Article | 01/16/2021 |
| RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer. | RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer.
Wang H, Huang R, Guo W, Qin X, Yang Z, Yuan Z, Wei Y, Mo C, Zeng Z, Luo J, Cai J, Wang H. | 12/26/2020 |
| Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells. | Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells.
Yin X, Zheng X, Liu M, Wang D, Sun H, Qiu Y, Chen J, Shi B. | 11/21/2020 |
| Association of Cyclin Dependent Kinase 10 and Transcription Factor 2 during Human Corneal Epithelial Wound Healing in vitro model. | Association of Cyclin Dependent Kinase 10 and Transcription Factor 2 during Human Corneal Epithelial Wound Healing in vitro model.
Zehra M, Mushtaq S, Ghulam Musharraf S, Ghani R, Ahmed N., Free PMC Article | 11/21/2020 |
| ETS2 promotes epithelial-to-mesenchymal transition in renal fibrosis by targeting JUNB transcription. | ETS2 promotes epithelial-to-mesenchymal transition in renal fibrosis by targeting JUNB transcription.
Yao F, Wang X, Cui ZK, Lan H, Ai X, Song Q, Chen Z, Yang J, Wu B, Bai X. | 09/26/2020 |
| Protein C-ets-2 epigenetically suppresses TLRs-induced interleukin 6 production in macrophages. | Protein C-ets-2 epigenetically suppresses TLRs-induced interleukin 6 production in macrophages.
Zhao J, Huang K, Peng HZ, Feng JF. | 09/5/2020 |
| ETS2 is highly expressed in p63-expressing prostatic carcinomas and benign prostate basal cells, with lower expression in luminal cells and primary usual-type adenocarcinomas. | ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL., Free PMC Article | 07/6/2019 |
| High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. | High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
Zhang G, Zhang L, Yang X, Zhang X, Zhang J, Yang S, Wang J, Hu K, Shi J, Ke X, Fu L. | 02/2/2019 |
| ETS2 is of potential value as a molecular target for RCC treatment. | Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway.
Zhang GW, Tian X, Li Y, Wang ZQ, Li XD, Zhu CY. | 10/13/2018 |
| ETS2 functions as an oncogene and plays a key role in the progression of hypopharyngeal cancer. | E26 Transformation-Specific Transcription Factor ETS2 as an Oncogene Promotes the Progression of Hypopharyngeal Cancer.
Liu X, Zhang C, Zhang Z, Zhang Z, Ji W, Cao S, Cai X, Lei D, Pan X. | 07/7/2018 |
| ETS2 (high) is a poor prognostic factor in acute myeloid leukemia and may guide treatment decisions towards allogeneic hematopoietic stem cell transplantation. | High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.
Fu L, Fu H, Wu Q, Pang Y, Xu K, Zhou L, Qiao J, Ke X, Xu K, Shi J., Free PMC Article | 06/2/2018 |
| Findings strongly suggest a critical role of Ets2 in human esophageal squamous cell carcinoma pathogenesis via the inactivation of the mTOR/p70S6K signaling pathway. | Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma in vivo and in vitro.
Li Q, Yang L, Han K, Zhu L, Zhang Y, Ma S, Zhang K, Yang B, Guan F., Free PMC Article | 02/3/2018 |
| Authors demonstrate that mtp53 prevents the COP1/DET1 complex from ubiquitinating ETS2 and thereby marking it for destruction. Authors show that mtp53 destabilizes DET1 and also disrupts the DET1/ETS2 complex thereby preventing ETS2 degradation. | Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation.
Carrero ZI, Kollareddy M, Chauhan KM, Ramakrishnan G, Martinez LA., Free PMC Article | 12/23/2017 |
| These findings suggest that ETS2 rs461155A>G, could be used as a biomarker predicting the clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. | A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Hong MJ, Lee SY, Choi JE, Jin CC, Kang HJ, Baek SA, Lee SY, Shin KM, Jeong JY, Lee WK, Yoo SS, Lee J, Cha SI, Kim CH, Son JW, Park JY., Free PMC Article | 12/9/2017 |
| Interaction with ZMYND11 mediates opposing roles of Ras-responsive ETS1 and ETS2. | Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2.
Plotnik JP, Hollenhorst PC., Free PMC Article | 09/9/2017 |